Serum factor blocks neuromuscular transmission in myasthenia gravis

We studied the effects of normal and myasthenic sera on the miniature endplate potential (MEPP) and resting membrane potential (RP) of rat muscle in vitro by conventional intracellular microelectrode techniques. Normal sera had little or no effect on either the amplitude or frequency of MEPP or RP. On the other hand, MEPP amplitude was reduced in each of nine muscles during exposure to myasthenic sera; five of these muscles showed a significant difference, by student's t-test, from the values in a control solution. The half decay time of diminished MEPP remained unchanged. MEPP frequency and RP were not affected by myasthenic sera. The reduced amplitude of the MEPP was almost completely restored when the muscle was washed with a control solution for more than 30 minutes. These observations indicate that myasthenic sera contain factors that bind reversibly with the acetylcholine receptor and reduce postsynaptic responses to acetylcholine.

[1]  S. Heinemann,et al.  Human myasthenic sera reduce acetylcholine sensitivity of human muscle cells in tissue culture , 1977, Nature.

[2]  A. Engel,et al.  Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. , 1977, Mayo Clinic proceedings.

[3]  D. Drachman,et al.  Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. , 1977, Science.

[4]  A. Pestronk,et al.  Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. , 1977, The New England journal of medicine.

[5]  J. Lindstrom,et al.  Antibody to acetylcholine receptor in myasthenia gravis , 1976, Neurology.

[6]  A. Engel,et al.  Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies , 1976, The Journal of experimental medicine.

[7]  S H Appel,et al.  EFFECTS OF NORMAL AND MYASTHENIC SERUM FACTORS ON INNERVATED AND CHRONICALLY DENERVATED MAMMALIAN MUSCLES , 1976, Annals of the New York Academy of Sciences.

[8]  J. Lindstrom,et al.  EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS AND MYASTHENIA GRAVIS: BIOCHEMICAL AND IMMUNOCHEMICAL ASPECTS * , 1976, Annals of the New York Academy of Sciences.

[9]  A. Pestronk,et al.  Myasthenia gravis: passive transfer from man to mouse , 1975, Science.

[10]  R. Almon,et al.  Acetylcholine receptor antibodies in myasthenia gravis. , 1975, The New England journal of medicine.

[11]  S. Fuchs,et al.  HUMORAL ANTIBODIES TO ACETYLCHOLINE RECEPTOR IN PATIENTS WITH MYASTHENIA GRAVIS , 1975, The Lancet.

[12]  R. Miledi,et al.  Neuromuscular transmission after immunization against acetylcholine receptors , 1975, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[13]  W. Engel,et al.  MYASTHENIA GRAVIS: A SERUM FACTOR BLOCKING ACETYLCHOLINE RECEPTORS OF THE HUMAN NEUROMUSCULAR JUNCTION , 1975, The Lancet.

[14]  C G Andrew,et al.  Serum Globulin in Myasthenia Gravis: Inhibition of α-Bungarotoxin Binding to Acetylcholine Receptors , 1974, Science.

[15]  R. Miledi,et al.  Transmitter release induced by a ‘factor’ in rabbit serum , 1974, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[16]  D. Drachman,et al.  Neuromuscular Junction in Myasthenia Gravis: Decreased Acetylcholine Receptors , 1973, Science.

[17]  J. Patrick,et al.  Autoimmune Response to Acetylcholine Receptor , 1973, Science.

[18]  B. Katz,et al.  On the factors which determine the amplitude of the ‘miniature end‐plate potential’ , 1957, The Journal of physiology.